JAK1 Cancer Research Results

JAK1, Janus kinase 1: Click to Expand ⟱
Source: CGL-Driver Genes
Type: Oncogene
One of the four members of the Janus kinase family and plays a significant role in the signaling pathways of various cytokines and growth factors, particularly those involved in immune responses. Its involvement in cancer has been increasingly recognized, as dysregulation of JAK1 signaling can contribute to tumorigenesis and cancer progression.
JAK1 is primarily associated with the signaling of several key cytokines, including interleukins (e.g., IL-2, IL-6, IL-10) and interferons. These cytokines are crucial for immune responses, and their dysregulation can lead to inhibitors, such as those targeting JAK1 specifically, are being investigated in clinical trials for various malignancies, including solid tumors and hematological cancers. an environment that supports cancer growth.
Scientific Papers found: Click to Expand⟱
6499- BCP,    JAK1/STAT3 regulatory effect of β-caryophyllene on MG-63 osteosarcoma cells via ROS-induced apoptotic mitochondrial pathway by DNA fragmentation
- in-vitro, OS, MG63
ROS↑, BCP induced reactive oxygen species (ROS) generation at 20 µM concentration in MG-63 cells.
Apoptosis↑, The same dose was also shown to exhibit proapoptotic and antiproliferative effects in bone cancer cells MG-63.
TumCP↓,
BAX↑, BCP prompted mitochondrial apoptosis via upregulation of Bax and caspase-3 and downregulation of Bcl-2 as well as prompted mitochondrial membrane potential.
Casp3↑,
Bcl-2↓,
MMP↓, The turn down in mitochondrial membrane potential was discover in concentrations (15 and 20 μM/mL) of BCP compared as control cancer cells.
DNAdam↑, DNA damage were increased in BCP (15 and 20 μM/mL) treated MG‐63 cells in a dose dependent manner.
TNF-α↓, Our results showed downregulation of all the inflammatory genes analyzed (TNF‐α, COX‐2, NF‐κB, and IL‐6) indicating an anti‐inflammatory property of BCP
COX2/PTGS2↓,
NF-kB↓,
IL6↓,
Inflam↓,
JAK1↑, increased levels of both JAK1 and STAT3 in MG‐63 cells upon treatment with BCP (15 and 20 μM/mL)
STAT3↑,

8095- KAE,    Kaempferol: A Key Emphasis to Its Anticancer Potential
- Review, Var, NA
*AntiBio↑, Kaempferol displays several pharmacological properties, among them antimicrobial, anti-inflammatory, antioxidant, antitumor, cardioprotective, neuroprotective, and antidiabetic activities, and is being applied in cancer chemotherapy.
*Inflam↓,
*AntiTum↓,
*antiOx↑, kaempferol contains hydroxyl groups at C3, C5, and C4, an oxo group at C4, and a double bond at C2-C3 that might explain its antioxidant activity
*cardioP↑,
*neuroP↑,
*AntiDiabetic↑,
Risk↓, Specifically, kaempferol-rich food has been linked to a decrease in the risk of developing some types of cancers, including skin, liver, and colon.
TumCCA↑, The mechanisms of action include apoptosis, cell cycle arrest at the G2/M phase, downregulation of epithelial-mesenchymal transition (EMT)-related markers, and phosphoinositide 3-kinase/protein kinase B signaling pathways.
EMT↓,
PI3K↓,
Akt↓, downregulation of signaling pathways and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), expression of epithelial-mesenchymal transition (EMT)-related markers (N-cadherin, E-cadherin, Snail, and Slug), and matrix metallopeptidase 2 (MMP-2),
MMP2↓,
Casp3↑, Kaempferol also induces the activation of cysteine proteases involved in apoptosis initiation and execution, caspases-3, -7, -9, and Poly (ADP-ribose) polymerase (PARP)
Casp7↑,
Casp9↑,
PARP↑,
*ROS↓, therefore preventing the accumulation of reactive oxygen species (ROS) involved in cancer development
angioG↓, The inhibition of angiogenesis was also reported as well as the capacity of kaempferol to preserve normal cell viability
*BioAv↑, To overcome the low bioavailability of kaempferol, its combination with quercetin increase its bioavailability, consequently improving its bio-efficacy.
BioAv↑, nanoformulations (e.g., nanoparticles, nanoemulsions, nanoencapsulation) containing kaempferol will be extremely beneficial in improving their bioavailability and consequent efficacy and selectivity for mutated cells,
selectivity↑, while their effect on normal cells will be limited. kaempferol exerts protective effects in non-mutated cells, whereas it triggers apoptosis in those mutated ones.
GLUT1↓, kaempferol also lowers the glucose transporter 1 (GLUT1) mRNA levels and prevents the uptake of (3)H-deoxy-d-glucose ((3)H-DG) and monocarboxylate transporter 1 (MCT1)-
MCT1↓,
ROS↓, Blocked ROS generation, cell cycle arrest at G1 and G2/M arrest, and cell migration
ROS↑, This flavonoid also triggers ROS generation and apoptosis, through reduction of the thioredoxin concentrations, superoxide dismutase activity
Trx↓,
Cyt‑c↑, Kaempferol is also able to release cytochrome c via ROS generation triggering mitochondrial membrane potential loss and mitochondrial swelling and increasing the level of cleaved caspase-3
MMP↓,
miR-21↓, Kaempferol also decreases the expression level of miR-21, cytokine signaling 3 (SOCS3), signal transducer and activator of transcription 3 (STAT3), CDK1, cyclin B, PI3K/AKT/mTOR and p-mTOR signaling pathway, and hypoxia-inducible factor 1 (HIF-1) in
SOCS-3↓,
STAT3↓,
CDK1↓,
CycB/CCNB1↑,
HIF-1↓,
JAK1↑, enhanced the expression of Janus kinase 1 (JAK1), tyrosine kinase 2 (Tyk2), STAT1/2, endogenous interferon (IFN)-α-regulated genes, phosphatase and tensin homologue (PTEN)
PTEN↑,


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↓, 1,   ROS↑, 2,   Trx↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 2,   Casp7↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   MCT1↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

miR-21↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CycB/CCNB1↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,   PI3K↓, 1,   PTEN↑, 1,   STAT3↓, 1,   STAT3↑, 1,  

Migration(tgid=13) ⓘ

MMP2↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   HIF-1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL6↓, 1,   Inflam↓, 1,   JAK1↑, 2,   NF-kB↓, 1,   SOCS-3↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

Risk↓, 1,  
Total Targets: 40

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   ROS↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↑, 1,   AntiTum↓, 1,   cardioP↑, 1,   neuroP↑, 1,  
Total Targets: 9

Scientific Paper Hit Count for: JAK1, Janus kinase 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:163  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page